Coviccine® --Recombinant COVID-19 Vaccine (Sf9 cell) by WestVac Biopharma is Available for Vaccination in Guizhou
2023-05-05
Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine® developed by WestVac Biopharma Co., Ltd. and West China Hospital of Sichuan University was launched in Guizhou. As one of the recommended vaccines in the national Immunization Schedule for Second COVID-19 Booster Dose, Coviccine® has excellent broad-spectrum immune protection against multiple mutant strains.
According to Lan Lan, Chief of the Immunization Department of the CDC in Qixingguan District, Bijie City, Guizhou Province, the Sporadic COVID-19 cases outbreak in China rural area still affects some population. In previous outbreaks, people who have not been infected and have not completed the established immunization program remain at risk of becoming infected and developing severe disease in the future; people who have been infected and have not completed basic immunization also have significantly weaker immune protection than those have cross-immunity obtained by reinfection after completing basic immunization due to insufficient vaccine or virus-induced antigen stimulation. In addition, protective antibodies will decline over time. In order to further strengthen the autoimmune ability, fill the gap in immune level, and reduce the risk of severe illness and death in the future, it is necessary to give a second booster dose to the population in a timely manner.
On April 10, the Joint Prevention and Control Mechanism of the State Council issued the "Vaccination Program to Respond to the Recent COVID-19 Infections" (hereinafter referred to as the "Program"), suggesting that relevant populations still need to actively complete vaccination against the COVID-19 to fill the immunization gap and further reduce the risk of serious illness and death. The Program clearly states that people who are not infected and have not completed the established immunization program need to receive the COVID-19 vaccine; those who are infected and have not completed the basic immunization need to receive one more dose of COVID-19 vaccine 3 months after infection. Recombinant COVID-19 vaccine or viral vector vaccine is recommended for sequential boosters. A sequential booster means that the third or fourth dose is given with a different type of vaccine than the first two or first three doses. Some clinical trials on sequential booster vaccination have shown that heterologous booster vaccination resulted in more durable immune response, which is one of the key reasons why the national authority is promoting sequential immunization,” said Lan Lan.
As one of the preferred vaccines in the national Immunization Schedule for Second COVID-19 Booster Dose, Coviccine® is the first recombinant COVID-19 vaccine (Sf9 cell) in China of good cross-immunity to SARS-CoV-2 variants such as Omicron, showing exceptional protection efficacy, good safety profile and tolerability in sequential booster vaccination among key populations such as population at high risk of infection, elderly population of 60 years and older, and population with underlying conditions.
It is reported that Coviccine® has been delivered to the vaccination sites in several districts and counties in Guizhou. Local residents eligible for vaccination may inquire information at the nearby site and make an appointment for vaccination. Since the approval for emergency use by the national authority in December 2022, Coviccine® has been on the vaccine procurement list in the bidding process in over 20 provinces, offering a better vaccine choice for the residents to meet their vaccination needs, and contributing to fight against COVID-19.
